Shell denies that it's pursuing a bid for BP, says no talks underway; stock up
The company also said that under U.K. regulations, making such a statement prevents it from making a formal offer for the next six months.
Shell's U.S.-listed shares rose 2% in premarket trading on the news by 05:22 ET, while BP shares slipped nearly 1%.
"Intensified speculation looks likely to see a degree of bid spec/ activism premium stick in BP shares for the immediate future," JPMorgan analysts said in a note.
The response came after a Wall Street Journal (WSJ) report on Wednesday claimed Shell was in discussions to acquire BP.
'In response to recent media speculation Shell wishes to clarify that it has not been actively considering making an offer for BP and confirms it has not made an approach to, and no talks have taken place with, BP with regards to a possible offer,' the oil giant said in the release.
'This is a statement to which Rule 2.8 of the Code applies and accordingly Shell confirms it has no intention of making an offer for BP. As a result Shell will be bound by the restrictions set out in Rule 2.8 of the Code,' it added.
The WSJ reported that Shell was in 'early-stage talks' to buy BP, citing sources familiar with the matter. The report said that the discussions between the two companies are 'active,' with BP said to be weighing the approach 'carefully.'
"We think market discussions are now likely to move towards trying to better understand the credibility and source of the latest news," UBS analysts commented.
"Shell may have denied talks are taking place but, no matter how unlikely a combination might be, we think the market will increase the probability of a deal happening, leading to an overhang on the shares in the near-term," they added.
"Any merger would require a rewriting of the Shell investment case which we believe, at least initially, would come to the detriment of shareholder confidence."
A potential acquisition of BP would present significant challenges for Shell, including a lengthy integration process, cultural differences, and likely divestments of overlapping assets.
However, such a move could expand Shell's already significant trading footprint and strengthen its position in key areas like liquefied natural gas.
Some analysts and investors believe the companies would be complementary in regions such as the Gulf of Mexico, now referred to by U.S. officials as the Gulf of America, the WSJ report added.
Under U.K. takeover rules, the six-month restriction on Shell making an offer for more than 30% of BP's shares could be lifted if BP invites a bid or if a competing offer for the company is made.
Related articles
Shell denies that it's pursuing a bid for BP, says no talks underway; stock up
Citi starts Sandisk at Buy on NAND recovery and enterprise SSD push; stock rises
Goldman Sachs starts Dutch Bros at 'neutral' on valuation, growth prospects
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
SM Energy (SM) Gets a Hold from Wells Fargo
Wells Fargo analyst Hanwen Chang maintained a Hold rating on SM Energy on July 18 and set a price target of $30.00. The company's shares closed last Friday at $25.89. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Chang covers the Energy sector, focusing on stocks such as Vital Energy, Matador Resources, and SM Energy. According to TipRanks, Chang has an average return of -2.8% and a 38.24% success rate on recommended stocks. In addition to Wells Fargo, SM Energy also received a Hold from J.P. Morgan's Zach Parham in a report issued on July 10. However, on July 16, Siebert Williams Shank & Co maintained a Buy rating on SM Energy (NYSE: SM). Based on SM Energy's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $844.54 million and a net profit of $182.27 million. In comparison, last year the company earned a revenue of $559.87 million and had a net profit of $131.2 million Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is neutral on the stock. Last month, Richard A. Jenkins, the SVP – Utah of SM sold 7,726.00 shares for a total of $220,113.74.
Yahoo
an hour ago
- Yahoo
Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT
AbbVie Inc. (NYSE:ABBV) is one of the best long term low volatility stocks to buy now. On July 10, Morgan Stanley analyst Terrence Flynn reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) and set a price target of $250.00. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) reported positive fiscal Q1 2025 results that support the optimistic outlook, with adjusted diluted EPS reaching $2.46, experiencing a 6.5% growth. The company also reported $13.343 billion in net revenue for the first quarter of 2025, reflecting an 8.4% growth on a reported basis or 9.8% on an operational basis. AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
an hour ago
- Yahoo
Thermo Fisher Scientific (TMO) Announces Strategic Partnership Expansion With Sanofi
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the best long term low volatility stocks to buy now. On July 16, Thermo Fisher Scientific Inc. (NYSE:TMO) announced plans to strategically expand its partnership with Sanofi to support additional drug product manufacturing in the United States. A workstation in a research lab stocked with laboratory products and services. As part of the partnership, Thermo Fisher Scientific Inc. (NYSE:TMO) would acquire Sanofi's manufacturing site in Ridgefield, New Jersey, and would continue to produce and develop a portfolio of therapies for Sanofi. Thermo Fisher Scientific Inc. (NYSE:TMO) also plans to expand use of the site to satisfy the rising demand from biotech and pharma customers for US manufacturing capacity. The Ridgefield site will join Thermo Fisher Scientific Inc. (NYSE:TMO) after the completion of the transaction, and comprises a state-of-the-art sterile fill-finish and packaging facility with over 200 employees. Thermo Fisher Scientific Inc. (NYSE:TMO) provides analytical instruments, reagents, equipment, software, and other services for analysis, research, diagnostics, and discovery. It operates through the Analytical Instruments, Life Sciences Solutions, Laboratory Products and Services, and Specialty Diagnostics segments. While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
